Maurizio Simmaco graduated in Medicine and Surgery in 1984, since 1989 he is specialist in Laboratory Medicine.
Since 1994 he is full professor of Biochemistry and Molecular Biology. He teaches at the Faculty of Medicine and Psychology of the Sapienza University of Rome. He is Director of the Clinical Biochemical Analysis Laboratory Unit of the Sant'Andrea University Hospital in Rome.
He is a member of the scientific bord of the European Society of Pharmacogenomics and Personalized Therapy (ESPT).
Scientific Activities:
- Primary structure of antioxidant proteins.
- Bioactive peptides with pharmacological and/or antibacterial activities from amphibian skin: structure, activity and identification of post-translational modifications in bioactive peptides.
- Phytotoxic lipodepsipeptides from Pseudomonas syringae.
- Proteomic studies on T lymphocytes (2DE/MALDI-ToF mass spectrometry) as biosensors.
- Pharmacogenomics and metabolomics.
- Personalized/Precision Medicine in clinical practice.
Publications:
EDUCATION
Academic career:
2003-present Full professor of Molecular Biology, Faculty of Medicine and Psychology, Sapienza University of Rome
2000-2003 Full professor of Biochemistry, II Faculty of Medicine, Sapienza University of Rome
1998-2000 Director of the Specialty School in Laboratory Medicine, University of Chieti
1994-2000 Full professor of Biochemistry, Faculty of Medicine, University of Chieti, Italy
1988-1994 Researcher at the National Research Council, Center of Molecular Biology
Hospital career:
2003-2017 Director of the Advanced Molecular Diagnosis Unit (DiMA), Sant'Andrea Hospital, Sapienza University of Rome
2017- present Director of Analytical Laboratory – Clinical Biochemistry and Advanced Molecular Diagnostics, Sant'Andrea University Hospital, Sapienza University of Rome
RESEARCH INTERESTS
- Primary structure of antioxidant proteins.
- Bioactive peptides peptides with pharmacological or antibacterial activities from amphibian skin: structure, activity and identification of post-translational modifications in bioactive peptides.
- Phytotoxic lipodepsipeptides from Pseudomonas syringae.
- Proteomic studies on T lymphocytes (2DE/MALDI-ToF mass spectrometry) as biosensors
- Pharmacogenomics and metabolomics
- Personalized/Precision Medicine
275
Scopus Publications
Scopus Publications
Investigating DRD2 and HTR2A polymorphisms in treatment-resistant schizophrenia: a comparative analysis with other treatment-resistant mental disorders and the healthy state Antonio Del Casale, Giovanna Gentile, Simone Lardani, Martina Nicole Modesti, Jan Francesco Arena, Clarissa Zocchi, Ottavia De Luca, Giovanna Parmigiani, Gloria Angeletti, Stefano Ferracuti, Robert Preissner, Maurizio Simmaco, Marina Borro, Maurizio Pompili European Archives of Psychiatry and Clinical Neuroscience, 2026 This study investigates treatment-resistant schizophrenia (TRS) by analysing genetic markers in dopamine and serotonin receptors. Conducted on a cohort of 221 patients with treatment-resistant mental disorders, the research focused on DRD2 and HTR2A gene variants—specifically, rs1801028, rs6314, rs7997012, and rs6311. The findings suggest specific associations between certain genetic variants and TRS. Notably, the HTR2A rs6314 A|G genotype and rs7997012 G|G genotype were significantly more prevalent in TRS patients compared to healthy controls (HCs). Haplotype analyses revealed associations between specific haplotypes—such as A|G (rs6314-rs7997012)—and TRS, indicating their potential predictive value for TRS versus HCs. The study underscores the involvement of the serotonergic system in TRS. These findings offer valuable insights into the genetic factors contributing to TRS, paving the way for future research and the development of personalised prevention and treatment strategies in psychiatry.
The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial Andrea Botticelli, Chiara Cremolini, Simone Scagnoli, Mauro Biffoni, Sara Lonardi, Lorenzo Fornaro, Valentina Guarneri, Ugo De Giorgi, Paolo Antonio Ascierto, Giovanni Blandino, Giulia D’Amati, Massimo Aglietta, Pierfranco Conte, Edoardo Crimini, Maurizio Ceracchi, Simona Pisegna, Sofia Verkhovskaia, Roberto Bordonaro, Sergio Bracarda, Giovanni Butturini, Lucia Del Mastro, Andrea DeCensi, Agnese Fabbri, Elisabetta Fenocchio, Stefania Gori, Giulio Metro, Annamaria Pessino, Daniele Pozzessere, Fabio Puglisi, Stefano Tamberi, Alberto Zambelli, Donatella Marino, Ettore Capoluongo, Federico Cappuzzo, Bruna Cerbelli, Giuseppe Giannini, Umberto Malapelle, Federica Mazzuca, Marianna Nuti, Giancarlo Pruneri, Maurizio Simmaco, Lidia Strigari, Giuseppe Tonini, Nello Martini, Giuseppe Curigliano, Paolo Marchetti Clinical Cancer Research, 2026 Purpose: This analysis evaluated the influence of tissue and liquid biopsy concordance on outcomes in patients enrolled in the ROME trial. Patients and Methods: The ROME trial, a phase II multicenter study, enrolled 1,794 patients with advanced solid tumors. Next-generation sequencing was performed on tissue and liquid biopsies using FoundationOne CDx and FoundationOne Liquid CDx. A centralized molecular tumor board reviewed results to identify actionable alterations, with 400 patients randomly assigned to tailored therapy (TT) or standard-of-care groups. TT improved objective response rate and progression-free survival (PFS) in the intention-to-treat population. Concordance was defined as the detection of the same druggable alteration in both biopsy types; discordance indicated detection in only one. Results: Concordance was present in 49% of cases, with alterations detected exclusively in tissue (35%) or liquid (16%) biopsies. Patients in the concordant group receiving TT experienced improved survival outcomes. The median overall survival was 11.05 versus 7.70 months in the standard-of-care group [HR = 0.74; 95% confidence interval, 0.51–1.07], and the median PFS was 4.93 versus 2.80 months (HR = 0.55; 95% confidence interval, 0.40–0.76), respectively. In contrast, the survival benefit of TT was less pronounced or absent in patients with discordant results. Overall survival was higher in the T + L group (11.05 months), followed by tissue-only (9.93 months) and liquid-only (4.05 months) groups. PFS followed a similar pattern, with the longest PFS in the T + L group (4.93 months) versus 3.06 months in tissue-only and 2.07 months in liquid-only groups. Conclusions: The study highlights the potential value of integrating both biopsy modalities in selected clinical contexts. See related commentary by Saldanha and Siu, p. 7
The Era of Precision Psychiatry: Toward a New Paradigm in Diagnosis and Care Antonio Del Casale, Liliana Bronzatti, Jan Francesco Arena, Giovanna Gentile, Carlo Lai, Paolo Girardi, Maurizio Simmaco, Marina Borro Psychiatry International, 2025 Mental disorders affect nearly one billion persons worldwide, having a substantial burden on individuals, families, and healthcare systems. Current diagnostic and therapeutic approaches could fail to reach optimal outcomes, highlighting the need for more effective and personalized interventions. Precision psychiatry aims to address this challenge by integrating multidimensional data, ranging from genomics and epigenomics to neuroimaging and psychometric assessments, through advanced computational tools such as machine learning and artificial intelligence. This transdisciplinary approach could allow the study of biologically informed endophenotypes, improve diagnostic accuracy, and support individualized treatment strategies. Emerging technologies, including pharmaco-neuroimaging, virtual histology, and large-scale consortia, are advancing the field by elucidating the molecular and circuit-level correlates of mental disorders. Although significant progress has been made, the translational gap between research and clinical practice remains a critical issue. Effective implementation will require the systematic integration of bioinformatic tools, big data analytics, and clinician-guided interpretation, in a context in which the evolving landscape of precision psychiatry continues to prioritize therapeutic alliance and individualized patient care.
Lipidomics and genomics in mental health: insights into major depressive disorder, bipolar disorder, schizophrenia, and obsessive-compulsive disorder Martina Nicole Modesti, Jan Francesco Arena, Antonio Del Casale, Giovanna Gentile, Marina Borro, Giovanna Parmigiani, Maurizio Simmaco, Cecilia Guariglia, Stefano Ferracuti Lipids in Health and Disease, 2025 INTRODUCTION: This systematic review explores the hypothesis that various lipid categories and lipid metabolism-related genomic variations link to mental disorders, seeking potential clinically useful markers. METHODS: We searched PubMed, Scopus, and PsycInfo databases until October 12th, 2024, using terms related to lipidomics, lipid-related genomics, and different mental disorders, i.e., Major Depressive Disorder (MDD), Bipolar Disorder (BD), Schizophrenia (SCZ), and Obsessive-Compulsive Disorder (OCD). Eligible studies were assessed. Extracted data included author, year, methodology, outcomes, genes, and lipids linked to disorders. Bias and evidence certainty were evaluated. The systematic review adhered to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines and a registered protocol (PROSPERO: CRD42023438862). RESULTS: A total of 27 studies were included. SCZ showed alterations in 77 lipids, including triglycerides (TG), ceramides, and phosphatidylcholine, while MDD and BD exhibited 97 and 47 altered lipids, respectively, with overlap among disorders. Shared genes, such as ABCA13, DGKZ, and FADS, and pathways involving inflammation, lipid metabolism, and mitochondrial function were identified. OCD was associated with sphingolipid signaling and peroxisomal metabolism. DISCUSSION: Lipid signatures in MDD, BD, and SCZ shed light on underlying processes. Further research is needed to validate biomarkers and refine their clinical applications in precision psychiatry.
Characterization of Gut Microbiota Profile in Lipedema: A Pilot Study Laura Di Renzo, Giulia Frank, Barbara Pala, Rossella Cianci, Gemma Lou De Santis, Francesco Nicoletti, Giulia Bigioni, Moreno Ortoman, Marina Borro, Maurizio Simmaco, Daniele Peluso, Antonino De Lorenzo, Paola Gualtieri Nutrients, 2025 Background: Lipedema is a progressive disorder of subcutaneous connective tissue, predominantly affecting women, and characterized by an increase in subcutaneous adipose tissue, particularly in the lower body. This study aims to explore the gut microbiota (GM) profile in lipedema patients to characterize the associated GM and compare it with the control group. Methods: A prospective randomized case–control pilot study was conducted from September 2023 to May 2024, involving 55 Caucasian women, aged 20–60. The participants were divided into two groups: 35 with lipedema (LIPPY) and 20 controls (CTRL). Body composition was assessed using Dual X-ray Absorbimetry (DXA), and GM analysis was performed through 16S rRNA gene sequencing. Results: LIPPY subjects showed increased Intramuscular Adipose Tissue (IMAT) and reduced Lean Mass (LM)/Fat Mass (FM) ratios. While alpha and beta diversity metrics did not differ significantly between groups, differential abundance analysis identified a significant reduction in Eggerthellaceae (Log Fold Change (LFC) = −0.19, p = 0.04) and enrichment of Propionibacteriaceae (LFC = +0.18, p = 0.009) and Acidaminococcaceae (LFC = +0.32, p = 0.013) in the LIPPY group. Genus-level analysis showed a significant reduction in Blautia and Ruminiclostridium (LFC = −0.32 and −0.02; p = 0.02 and 0.04) and enrichment of Anaerostipes, Propionibacterium, and Phascolarctobacterium (LFC = +0.07, +0.17, and +0.34; p = 0.02, 0.005, 0.005, respectively). In correlation analyses, within LIPPY, Eggerthellaceae correlated negatively with Body Mass Index (BMI) (ρ = −0.61, p < 0.05) and positively with Appenicular (Appen) LM/Weight and AppenLM/BMI (ρ = +0.43 and +0.41, p < 0.05), while Anaerostipes correlated positively with these lean mass indices (ρ = +0.40, p < 0.05). In CTRL, only Anaerostipes showed a significant negative correlation with BMI (ρ = −0.64, p < 0.05). Conclusions: This study provides the first evidence of a distinct GM profile in LIPPY, with notable links to adverse body composition markers such as IMAT. Trial Registration: Trial registered on 24 June 2013 with ClinicalTrial.gov (NCT01890070).
The role of 5-hydroxytryptamine receptor 2A (HTR2A) gene polymorphisms in treatment-resistant obsessive–compulsive disorder: a comparative study with other treatment-resistant mental disorders Antonio Del Casale, Giovanna Gentile, Jan Francesco Arena, Martina Nicole Modesti, Clarissa Zocchi, Serena Mancino, Ottavia De Luca, Gloria Angeletti, Stefano Ferracuti, Robert Preissner, Maurizio Pompili, Maurizio Simmaco, Marina Borro BMC Psychiatry, 2025 BACKGROUND: This study investigates the role of genetic variations in the 5-Hydroxytryptamine Receptor 2A (HTR2A) gene in subjects with treatment-resistant obsessive-compulsive disorder (TR-OCD), compared to individuals with other treatment-resistant mental disorders (TRMDs). The goal is to explore whether specific HTR2A polymorphisms contribute to distinguishing TR-OCD from other TRMDs, thereby advancing our understanding of the underlying pathophysiological mechanisms. METHODS: A retrospective observational study was conducted with 210 individuals affected by TRMDs (72 with major depressive disorder, 62 with bipolar disorder, 37 with schizophrenia, 30 with OCD, and 9 with other diagnoses). Genetic analyses focused on three HTR2A single nucleotide polymorphisms (SNPs) (rs6314, rs7997012, and rs6311), using next-generation sequencing from blood samples. Chi-square testing and single- and multiple-SNP analyses were employed to study the association between these SNPs and the TR-OCD diagnosis. RESULTS: The analysis revealed that the HTR2A rs7997012 A|A vs. G|G genotype was significantly associated with a higher likelihood of belonging to the TR-OCD group compared to other TRMDs, with an odds ratio of 6.85 (95% CI = 2.44-19.26; p < 0.001). The same genotype, compared to the combined G|G and A|G genotypes, showed a significant association with TR-OCD (OR = 7.68; 95% CI = 2.90-20.34; p < 0.001). Haplotype analyses demonstrated a significant global association between the combined rs6314-rs7997012-rs6311 variants and TR-OCD (p = 0.028). Specifically, the G-G-C haplotype was significantly associated with a reduced likelihood of TR-OCD (OR = 0.32; 95% CI = 0.11-0.93; p = 0.038) compared to the reference haplotype G-G-T. CONCLUSIONS: This preliminary study identifies the rs7997012 polymorphism in the HTR2A gene as a potential genetic marker for TR-OCD, distinguishing it from other TRMDs. The study of rs7997012 and other genetic variants within the serotonergic system may enhance our understandings of the biological mechanisms underlying OCD and contribute to the development of precision psychiatry approaches.
High-Throughput Molecular Characterization of the Microbiome in Breast Implant-Associated Anaplastic Large Cell Lymphoma and Peri-Implant Benign Seromas Evelina Rogges, Giorgio Bertolazzi, Davide Vacca, Marina Borro, Gianluca Lopez, Maurizio Simmaco, Anna Scattone, Guido Firmani, Michail Sorotos, Fabio Santanelli di Pompeo, Niccolò Noccioli, Emanuele Savino, Andrea Vecchione, Arianna Di Napoli Cancers, 2025 Background: Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a mature T-cell lymphoma linked to textured breast implants. A leading hypothesis suggests that chronic inflammation, combined with immunological and genetic factors, drives its pathogenesis. Two previous studies investigating bacterial biofilms on breast implant capsules have produced conflicting results, particularly regarding the enrichment of Ralstonia spp. Methods: We analyzed the microbiota profiles in seroma samples from 10 BIA-ALCL patients and 12 patients with non-neoplastic effusion, subclassified into acute-, mixed-, and chronic-type based on cellular composition. We used two metagenomic approaches: 16S rRNA gene sequencing and Nanopore sequencing with the “What’s in My Pot?” (WIMP) taxonomic classifier. Our analyses included alpha and beta diversity metrics, as well as comparisons of Gram status and oxygen requirements. Results: Both sequencing methods identified Staphylococcaceae, Propionibacteriaceae, and Bradyrhizobiaceae as the most prevalent bacterial families in both BIA-ALCL and benign seroma samples. Notably, the Burkholderiaceae family was more abundant in some of the benign seromas according to the 16S rRNA sequencing, but Ralstonia spp. were not detected. BIA-ALCL showed higher richness (based on Nanopore data) and higher evenness (based on 16S rRNA data) compared to acute-type seromas, indicating a more homogenous representation of the different taxa identified. BIA-ALCL seromas did not cluster together based on Nanopore data, but they did form a distinct cluster with 16S rRNA data. This cluster was differentiated from the other two clusters by a relatively balanced presence of multiple families without overt dominance. We observed no significant differences in Gram staining between BIA-ALCL and benign samples using either method. However, non-aerobic bacterial families were enriched in BIA-ALCL cases only when analyzed with the Nanopore pipeline. Conclusions: Overall, our findings did not identify a distinctive microbial signature specifically associated with BIA-ALCL.
Preclinical and clinical study on type 3 metabotropic glutamate receptors in Parkinson’s disease Luisa Di Menna, Marika Alborghetti, Maria Ilenia De Bartolo, Marina Borro, Giovanna Gentile, Manuela Zinni, Matteo Bologna, Carolina Cutrona, Giovanna D’Errico, Tiziana Imbriglio, Domenico Bucci, Sara Merlo, Roxana Paula Ginerete, Rosamaria Orlando, Federica Carrillo, Giorgio Fortunato, Milena Cannella, Maria Angela Sortino, Julien Pansiot, Olivier Baud, Ferdinando Nicoletti, Valeria Bruno, Maurizio Simmaco, Francesco Ernesto Pontieri, Edoardo Bianchini, Domiziana Rinaldi, Amalia de Curtis, Giovanni De Gaetano, Licia Iacoviello, Teresa Esposito, Alfredo Berardelli, Giuseppe Battaglia Npj Parkinson S Disease, 2025 Metabotropic glutamate (mGlu) receptors are candidate drug targets for therapeutic intervention in Parkinson’s disease (PD). Here we focused on mGlu3, a receptor subtype involved in synaptic regulation and neuroinflammation. mGlu3 −/− mice showed an enhanced nigro-striatal damage and microglial activation in response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Expression of genes encoding anti-inflammatory proteins and neuroprotective factors was reduced in the striatum of MPTP-treated mGlu3 −/− mice. We also examined polymorphic variants of GRM3 (the mGlu3 receptor encoding gene) in 723 PD patients and 826 healthy controls. Two GRM3 haplotypes were associated with PD, and gene variants correlated with motor and non-motor signs. Interestingly, PD patients carrying each of the two haplotypes showed an impaired cortical plasticity in the paired associated stimulation paradigm of magnetic transcranial stimulation. These findings suggest that mGlu3 receptors are neuroprotective in mouse models of parkinsonism and shape mechanisms of cortical plasticity in PD.
Epilepsy expands the phenotype of L-arginine:glycine amidinotransferase deficiency Alessandro Ferretti, Roberta Battini, Olga Gagliardo, Daniela Verrigni, Maria Beatrice Manca, Anna Rita Ferrari, Gerardo Salerno, Rosanna Boccia, Daniela Polese, Chiara Cocco, Stefania Zampogna, Giovanni Di Nardo, Melania Evangelisti, Jacopo Pagani, Oliviero Bruni, Andrea Romano, Marco Piastra, Maurizio Simmaco, Monica Rocco, Antonio Novelli, Claudia Carducci, Alessandro Bozzao, Pasquale Parisi Epilepsia, 2025 ObjectiveL‐arginine:glycine amidinotransferase (AGAT) deficiency is a rare autosomal recessive disorder affecting creatine biosynthesis, leading to developmental delay, intellectual disabilities, and myopathy. Unlike other creatine deficiency disorders, its link to epilepsy remains uncertain. This study presents the first reported epilepsy cases in AGAT deficiency, analyzing seizure patterns and response to creatine monohydrate supplementation.MethodsWe retrospectively analyzed two AGAT‐deficient probands identified through a national collaboration. Biochemical assessments of creatine and guanidinoacetate (GAA) levels in plasma and urine were performed using electrospray ionization tandem mass spectrometry and high‐performance liquid chromatography methods. Brain magnetic resonance spectroscopy was conducted to evaluate cerebral creatine levels pre‐ and postsupplementation.ResultsBoth probands carried the homozygous c.446G>A, p.(Trp149Ter) mutation in GATM, classified as pathogenic. The first, diagnosed at birth and treated with creatine from 4 months, had normal psychomotor development but developed focal epilepsy at 6 years, controlled with carbamazepine. The second, diagnosed at 5 years, presented with psychomotor delay, behavioral disturbances, and nocturnal seizures with unknown origin from age 4 years, later developing focal tonic seizures while awake. Initially the proband was unresponsive to carbamazepine; seizure control was achieved with valproate and lacosamide. Definitive conclusions on the role of creatine supplementation in epilepsy associated with AGAT deficiency cannot be drawn, as it was not modified after seizure onset in the first proband and introduced only after seizure control in the second.SignificanceThis study presents the first cases of epilepsy in AGAT deficiency, suggesting its prevalence may be underestimated. AGAT‐related epilepsy appears to be part of the associated developmental encephalopathy, with focal seizures and minimal impact on psychomotor development. In AGAT deficiency, epilepsy is not linked to GAA accumulation as in other creatine deficiency disorders but rather to low brain creatine levels, which may affect γ‐aminobutyric acidergic neurotransmission and seizure thresholds. The role of creatine supplementation in seizure control warrants further investigation.
Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study Simone Scagnoli, Simona Pisegna, Angela Toss, Roberta Caputo, Michelino De Laurentiis, Michela Palleschi, Ugo de Giorgi, Enrico Cortesi, Agnese Fabbri, Alessandra Fabi, Ida Paris, Armando Orlandi, Giuseppe Curigliano, Carmen Criscitiello, Ornella Garrone, Gianluca Tomasello, Giuliana D’Auria, Patrizia Vici, Enrico Ricevuto, Federica Domati, Claudia Piombino, Sara Parola, Roberta Scafetta, Alessio Cirillo, Beatrice Taurelli Salimbeni, Francesca Sofia Di Lisa, Lidia Strigari, Robert Preissner, Maurizio Simmaco, Daniele Santini, Paolo Marchetti, Andrea Botticelli Npj Breast Cancer, 2024
Correction to: Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study (npj Breast Cancer, (2024), 10, 1, (58), 10.1038/s41523-024-00657-z) Simone Scagnoli, Simona Pisegna, Angela Toss, Roberta Caputo, Michelino De Laurentiis, Michela Palleschi, Ugo de Giorgi, Enrico Cortesi, Agnese Fabbri, Alessandra Fabi, Ida Paris, Armando Orlandi, Giuseppe Curigliano, Carmen Criscitiello, Ornella Garrone, Gianluca Tomasello, Giuliana D’Auria, Patrizia Vici, Enrico Ricevuto, Federica Domati, Claudia Piombino, Sara Parola, Roberta Scafetta, Alessio Cirillo, Beatrice Taurelli Salimbeni, Francesca Sofia Di Lisa, Lidia Strigari, Robert Preissner, Maurizio Simmaco, Daniele Santini, Paolo Marchetti, Andrea Botticelli Npj Breast Cancer, 2024
Opioid Use and Gut Dysbiosis in Cancer Pain Patients Flaminia Coluzzi, Maria Sole Scerpa, Chiara Loffredo, Marina Borro, Joseph V. Pergolizzi, Jo Ann LeQuang, Elisa Alessandri, Maurizio Simmaco, Monica Rocco International Journal of Molecular Sciences, 2024
The Drug-PIN® support in elderly diabetics with high polypathology scores by the MCPS: A preliminary approach to reduce the risk of polypharmacy International Journal on Disability and Human Development, 2024
The Third Dose of BNT162b2 COVID-19 Vaccine Does Not “Boost” Disease Flares and Adverse Events in Patients with Rheumatoid Arthritis Andrea Picchianti Diamanti, Assunta Navarra, Gilda Cuzzi, Alessandra Aiello, Simonetta Salemi, Roberta Di Rosa, Chiara De Lorenzo, Daniele Vio, Giandomenico Sebastiani, Mario Ferraioli, Maurizio Benucci, Francesca Li Gobbi, Fabrizio Cantini, Vittoria Polidori, Maurizio Simmaco, Esmeralda Cialdi, Palma Scolieri, Vincenzo Bruzzese, Emanuele Nicastri, Raffaele D’Amelio, Bruno Laganà, Delia Goletti Biomedicines, 2023
Machine Learning and Pharmacogenomics at the Time of Precision Psychiatry Antonio Del Casale, Giuseppe Sarli, Paride Bargagna, Lorenzo Polidori, Alessandro Alcibiade, Teodolinda Zoppi, Marina Borro, Giovanna Gentile, Clarissa Zocchi, Stefano Ferracuti, Robert Preissner, Maurizio Simmaco, Maurizio Pompili Current Neuropharmacology, 2023
Opposite Effect of Thyroid Hormones on Oxidative Stress and on Mitochondrial Respiration in COVID-19 Patients Claudia De Vitis, Carlo Capalbo, Alessandra Torsello, Christian Napoli, Valentina Salvati, Chiara Loffredo, Giovanni Blandino, Giulia Piaggio, Francesca Romana Auciello, Flaminia Pelliccia, Gerardo Salerno, Maurizio Simmaco, Laura Di Magno, Gianluca Canettieri, Flaminia Coluzzi, Rita Mancini, Monica Rocco, Salvatore Sciacchitano Antioxidants, 2022
Prevalence of SARS-CoV-2 IgG antibodies in an area of northeastern Italy with a high incidence of COVID-19 cases: a population-based study Paola Stefanelli, Antonino Bella, Giorgio Fedele, Serena Pancheri, Pasqualina Leone, Paola Vacca, Arianna Neri, Anna Carannante, Cecilia Fazio, Eleonora Benedetti, Stefano Fiore, Concetta Fabiani, Maurizio Simmaco, Iolanda Santino, Maria Grazia Zuccali, Giancarlo Bizzarri, Rosa Magnoni, Pier Paolo Benetollo, Stefano Merler, Silvio Brusaferro, Giovanni Rezza, Antonio Ferro Clinical Microbiology and Infection, 2021
Increased kynurenine-to-tryptophan ratio in the serum of patients infected with SARS-CoV2: An observational cohort study. Luana Lionetto, Martina Ulivieri, Matilde Capi, Donatella De Bernardini, Francesco Fazio, Andrea Petrucca, Leda Marina Pomes, Ottavia De Luca, Giovanna Gentile, Barbara Casolla, Martina Curto, Gerardo Salerno, Serena Schillizzi, Maria Simona Torre, Iolanda Santino, Monica Rocco, Paolo Marchetti, Antonio Aceti, Alberto Ricci, Rita Bonfini, Ferdinando Nicoletti, Maurizio Simmaco, Marina Borro Biochimica Et Biophysica Acta Molecular Basis of Disease, 2021
Serum S100B protein as a marker of severity in Covid-19 patients Antonio Aceti, Lory Marika Margarucci, Elena Scaramucci, Massimiliano Orsini, Gerardo Salerno, Gabriele Di Sante, Gianluca Gianfranceschi, Rosa Di Liddo, Federica Valeriani, Francesco Ria, Maurizio Simmaco, Pier Paolo Parnigotto, Matteo Vitali, Vincenzo Romano Spica, Fabrizio Michetti Scientific Reports, 2020
The exponential phase of the covid-19 pandemic in central Italy: An integrated care pathway Carlo Capalbo, Antonio Aceti, Maurizio Simmaco, Rita Bonfini, Monica Rocco, Alberto Ricci, Christian Napoli, Matteo Rocco, Valeria Alfonsi, Antonella Teggi, Giovanni Battista Orsi, Marina Borro, Iolanda Santino, Robert Preissner, Paolo Marchetti, Adriano Marcolongo, Paolo Anibaldi International Journal of Environmental Research and Public Health, 2020
Migraine and cluster headache show impaired neurosteroids patterns Angela Koverech, Claudia Cicione, Luana Lionetto, Marta Maestri, Francesco Passariello, Elisabetta Sabbatini, Matilde Capi, Cristiano Maria De Marco, Martina Guglielmetti, Andrea Negro, Luisa Di Menna, Maurizio Simmaco, Ferdinando Nicoletti, Paolo Martelletti Journal of Headache and Pain, 2019
4th ESPT summer school: Precision medicine and personalised health Vid Mlakar, Janja Marc, Vangelis G Manolopoulos, Ingolf Cascorbi, Sanja Stanković, Adrian Llerena, Maurizio Simmaco, Sophie Visvikis-Siest, Ursula Amstutz, Csilla Sipeky, Urs A Meyer, Peter Meier-Abt, Ron H van Schaik, Marc Ansari Pharmacogenomics, 2019
Mitochondrial myopathy and comorbid major depressive disorder: Effectiveness of dTMS on gait and mood symptoms Chiara Rapinesi, Delfina Janiri, Georgios D. Kotzalidis, Daniele Serata, Antonio Del Casale, Paola Scatena, Claudia Dacquino, Giovanna Gentile, Giovanni Manfredi, Emanuela Danese, Ruggero Nessim Raccah, Roberto Brugnoli, Gemma Callovini, Vittoria Rachele Ferri, Stefano Ferracuti, Abraham Zangen, Maurizio Simmaco, Gloria Angeletti, Paolo Girardi General Hospital Psychiatry, 2015
Intramuscular aripiprazole in the acute management of psychomotor agitation Sergio De Filippis, Ilaria Cuomo, Luana Lionetto, Delfina Janiri, Maurizio Simmaco, Matteo Caloro, Simone De Persis, Gioia Piazzi, Alessio Simonetti, C Ludovica Telesforo, Antonio Sciarretta, Federica Caccia, Giovanna Gentile, Georgios D. Kotzalidis, Paolo Girardi Pharmacotherapy, 2013
The omics in migraine Luana Lionetto, Giovanna Gentile, Elisa Bellei, Matilde Capi, Donata Sabato, et al. Journal of Headache and Pain, 2013
Gene variants with suicidal risk in a sample of subjects with chronic migraine and affective temperamental dysregulation European Review for Medical and Pharmacological Sciences, 2012
Pharmacokinetic evaluation of frovatriptan Andrea Negro, Luana Lionetto, Barbara Casolla, Noemi Lala, Maurizio Simmaco, et al. Expert Opinion on Drug Metabolism and Toxicology, 2011
Tryptic cleavage as a probe of conformational differences between active and inactive forms of ornithine aminotransferase Journal of Biological Chemistry, 1989
Assessment of the extent of proteolysis of native ornithine aminotransferase by electroblotting and microsequencing methodologies Journal of Protein Chemistry, 1988
Multiple forms of syringomycin Alessandro Ballio, Donatella Barra, Francesco Bossa, James E. DeVay, Ingeborg Grgurina, et al. Physiological and Molecular Plant Pathology, 1988
